Pfizer Inc. Completes Pneumococcal Pneumonia Case Accrual For CAPiTA, Adult Vaccine Clinical Trial of Prevenar 13*

Published: Aug 29, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today the completion of pneumonia case accrual in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) 65 years of age and older. CAPiTA, the largest trial of its kind, was designed to evaluate whether Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) is effective in preventing community-acquired pneumonia (CAP) caused by the 13 pneumococcal serotypes included in the vaccine.1 It is an event-driven clinical study, meaning that a pre-specified number of community-acquired, vaccine-type pneumococcal pneumonia cases have to occur among study participants before the results can be determined.

Help employers find you! Check out all the jobs and post your resume.

Back to news